Date: 2016-03-21
Type of information: Development agreement
Compound: gene therapy product for the treatment of multiple myeloma
Company: Molmed (Italy) Genenta Science (Italy)
Therapeutic area: Cancer - Oncology - Rare diseases
Type agreement: development manufacturing production collaboration
Action mechanism: gene therapy
Disease: multiple myeloma
Details: * On March 21, 2016, MolMed and Genenta Science signed an agreement on a multi-year cooperation to develop and manufacture a gene therapy product for the treatment of multiple myeloma. In accordance to this agreement, MolMed will develop and validate the manufacturing and analytical methods of the Genenta product that constitute part of the preparatory activities to enter in the clinical trials. Furthermore, MolMed will support Genenta to file the application dossier required for the authorisation to proceed with trials.
The agreement extends the collaboration by ensuring MolMed exclusive product manufacturing for the clinical trials, in which the gene therapy for multiple myeloma will be investigated.
Genenta Science develops a gene transfer strategy into autologous hematopoietic stem cells (HSCs) to target interferon-? expression to tumor-infiltrating monocytes/macrophages. An HIV-derived and genetically disabled viral vector - Lentivirus - delivers the gene into the HSCs. Interferon is a protein usually produced by the body in response to infections that also exhibits a pleiotropic anti-tumor activity. However, the clinical use of interferon-? as a drug has been limited by its high toxicity. The innovative therapy of Genenta Science, by combining transcriptional and microRNA-mediated control, enables tumor-infiltrating monocytes/macrophages to selectively express interferon-? limited to the tumor area, thus reducing its toxicity.
Financial terms:
Latest news:
